These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38572561)
1. Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib. Geçgel A; Ön S; Çiftçi Y; Özkan O; Açar FP; Karaca B Balkan Med J; 2024 Jul; 41(4):312-313. PubMed ID: 38572561 [No Abstract] [Full Text] [Related]
2. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. Zaloum A; Falet JR; Elkrief A; Chalk C Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971 [No Abstract] [Full Text] [Related]
3. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide. Hussar DA; Kaminski JL J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134 [No Abstract] [Full Text] [Related]
5. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib. Sawada H; Kanehisa F; Katoh N; Asai J J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335 [No Abstract] [Full Text] [Related]
6. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408 [TBL] [Abstract][Full Text] [Related]
7. A Case Report and Literature Review of Vogt-Koyanagi-Harada-Like Uveitis Secondary to Dabrafenib and Trametinib: 4-Year Follow-Up Using Retinal Multimodal Imaging. Ucan Gunduz G; Gullulu ZZ; Nizam Tekcan S; Yalcinbayir O; Cubukcu E Ocul Immunol Inflamm; 2024 Dec; 32(10):2589-2593. PubMed ID: 39250693 [TBL] [Abstract][Full Text] [Related]
8. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Lee le M; Feun L; Tan Y Am J Case Rep; 2014 Oct; 15():441-3. PubMed ID: 25305754 [TBL] [Abstract][Full Text] [Related]
9. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib. Avila C; Hoffman K; Milani-Nejad N; Pootrakul L Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032 [TBL] [Abstract][Full Text] [Related]
10. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib. Martínez-Rodríguez I; García-Castaño A; Quirce R; Jiménez-Bonilla J; Banzo I Clin Nucl Med; 2017 Jan; 42(1):44-46. PubMed ID: 27775948 [TBL] [Abstract][Full Text] [Related]
11. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma. Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385 [No Abstract] [Full Text] [Related]
12. Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis. Hajikarimloo B; Habibi MA; Kooshki A; Alvani MS; Zare AH; Hasanzade A; Zare AH; Akhlaghpasand M; Tavanaei R; Tos SM BMC Cancer; 2024 Nov; 24(1):1473. PubMed ID: 39614165 [TBL] [Abstract][Full Text] [Related]
13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
14. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib. Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336 [No Abstract] [Full Text] [Related]
15. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study. Martín Algarra S; Soriano V; Fernández-Morales L; Berciano-Guerrero MÁ; Mujika K; Manzano JL; Puértolas Hernández T; Soria A; Rodríguez-Abreu D; Espinosa Arranz E; Medina Martínez J; Márquez-Rodas I; Rubió-Casadevall J; Ortega ME; Jurado García JM; Lecumberri Biurrun MJ; Palacio I; Rodríguez de la Borbolla Artacho M; Altozano JP; Castellón Rubio VE; García A; Luna P; Ballesteros A; Fernández O; López Martín JA; Berrocal A; Arance A Medicine (Baltimore); 2017 Dec; 96(52):e9523. PubMed ID: 29384960 [TBL] [Abstract][Full Text] [Related]
17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
18. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF White PS; Pudusseri A; Lee SL; Eton O Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037 [No Abstract] [Full Text] [Related]
20. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]